Lewy body dementia (LBD) is the second most common form of progressive dementia after Alzheimer’s disease, encompassing both dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). Despite affecting more than 1.4 million Americans, LBD remains underrecognized, frequently misdiagnosed, and without any FDA-approved or disease-modifying treatments. To help address these unmet needs, the Lewy Body Dementia Association established its Industry Advisory Council in 2019, bringing together leaders from academia, industry, and government to advance diagnostic and therapeutic innovation in LBD.

A Next-Generation Advisory Council

Building on this foundation, LBDA is evolving the Industry Advisory Council into a fully integrated, cross-sector Advisory Council—a strategic engine designed to accelerate translational research, biomarker development, and clinical progress in LBD.

The re-envisioned Advisory Council brings together clinical experts, regulatory leaders, life-science innovators, data scientists, patients, care partners, and global collaborators around a shared, action-oriented mission: to advance LBD research and drug development through coordination, consensus, and measurable impact.

Strategic Focus Areas

The Advisory Council serves as a central hub for scientific collaboration and translational alignment, with priorities that include:

• Biomarker advancement
• Regulatory engagement
• Data aggregation and harmonization
• Clinical network enablement
• Global collaboration
• Patient and caregiver integration

LBDA deeply values the leadership and engagement of its corporate partners. This support is essential to drive the next era of innovation, impact, and global progress for the LBD community.

If you are interested in learning more about the Advisory Council, please contact Eileen Priest ([email protected]) or Sudhir Sivakumaran ([email protected])

Advisory Council Members